Clinical Trials Logo

Filter by:
NCT ID: NCT03311542 Temporarily not available - Melanoma (Skin) Clinical Trials

Expanded Access for Pembrolizumab (MK-3475)

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

NCT ID: NCT03288870 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer Stage IIIB

A Study of Efficacy, Safety and Pharmacokinetics of BCD-100 Monotherapy as Second Line Treatment of Patients With Non-small Cell Lung Cancer

Start date: October 15, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced inoperable or metastatic non-small cell lung cancer

NCT ID: NCT03259269 Recruiting - Clinical trials for Tuberculosis, Multidrug-Resistant

Expand New Drugs for TB [endTB]

Start date: February 9, 2016
Phase: N/A
Study type: Observational

This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB. The information gathered in this study will inform doctors how best to use these TB drugs in the future.

NCT ID: NCT03164070 Enrolling by invitation - Osteoarthritis Clinical Trials

Study of the Laboratory-based Evaluation of the Degrees of Activity of Osteoarthritis

Start date: July 1, 2016
Phase: N/A
Study type: Observational

This study evaluates laboratory-based method to estimate the degrees of activity of medium and large joint osteoarthritis.

NCT ID: NCT03164044 Enrolling by invitation - Drug Allergy Clinical Trials

Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy

Start date: January 3, 2017
Phase: N/A
Study type: Observational

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).

NCT ID: NCT03114631 Enrolling by invitation - Clinical trials for Pancreatic Neoplasms

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Start date: January 9, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed dendritic cell Immunotherapy for the patients with pancreatic cancer

NCT ID: NCT03072576 Recruiting - Clinical trials for Tuberculosis, Pulmonary

Accuracy and Feasibility of Xpert Ultra

Start date: March 2016
Phase: N/A
Study type: Observational

Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis and rifampin resistance.

NCT ID: NCT03062644 Recruiting - Acute Pain Clinical Trials

Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.

Start date: April 5, 2017
Phase: Phase 3
Study type: Interventional

The MR308-3502 study is a multicenter double-blind, randomised, placebo- and active comparator-controlled study in female subjects to evaluate the efficacy and safety of MR308 with acute pain after TAH or STAH (total or subtotal abdominal hysterectomy).

NCT ID: NCT03061812 Recruiting - Clinical trials for Small Cell Lung Cancer

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Start date: April 10, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this randomized, open-label, 2-arm, Phase 3 study is to assess the assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic Small Cell Lung Cancer (SCLC) with high levels of delta-like protein 3 (DLL3) and who have first disease progression during or following front-line platinum-based chemotherapy.

NCT ID: NCT03045302 Terminated - Acromegaly Clinical Trials

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

Start date: January 26, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.